spacer
home > epc > autumn 2008 > home work
PUBLICATIONS
European Pharmaceutical Contractor

Home Work

In recent decades the types of therapy in research and the marketplace have undergone some radical transformations. Where most therapies were once squarely aimed at endemic diseases of the West, the recent biotechnology revolution has hugely increased the number of therapeutic targets, with more complex medicines – often parenteral – aimed at less common illnesses or at more specific sub groups of patients with more common conditions. For example, we are seeing oncology therapies targeting smaller sub groups of patients, the rise of therapies for orphan indications, the targeting of antibodies and proteins for specific complications of illness such as preventing SLE crisis and so on. The drive towards community medicine means an infrastructure has grown up to administer these medicines in the home and to run clinical trials in the same way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Graham Wylie is CEO of the Medical Research Network Ltd, an affiliate company of Healthcare at Home. Graham, who trained as a physician, has 18 years of experience in clinical trials, starting with 10 years at Pfizer in clinical development and corporate HQ, with roles ranging from project management of trials to global implementation of standard trial processes and IT tools. He then joined Parexel International in 1999 as Medical Director for Northern Europe, progressing to Vice President of Account Management for Europe by 2003. In 2005 he joined Healthcare at Home to develop their clinical trials activities into a full business unit, known as ‘The Medical Research Network’, spinning the division off as a separate company in 2006.
spacer
Dr Graham Wylie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement